UBS Downgrades Epiroc to Sell, Highlights 17% Potential Drop Amid Stretched Valuation

UBS has shifted gears on Epiroc AB, moving the stock from neutral to sell. The bank raised its 12-month price target to SKr230 from SKr200 but flagged the current price run-up as overly aggressive. Investors saw the shares take a hit, dropping about 4.6% as of early trading.

The jump in Epiroc's stock - which has jumped 32% YTD and outpaced its industry peers by roughly 18 percentage points - seems to have left UBS skeptical about the sustainability of that rally. The stock closed at SKr277 on June 22, hinting at about 17% room for a potential pullback according to the bank's latest target.

UBS points out that Epiroc's traditionally strong valuation premium has become strained. Trading at a forward EV/EBIT multiple of 22.4x - roughly 17% above its five-year average - the figures appear inflated compared to past norms. Moreover, UBS's reverse discounted cash flow forecasts suggest the current price already factors in quite a bit: 15% revenue growth annually and margin expansion that surpasses historical peaks by 2029.

Despite Epiroc's impressive first-quarter performance, including a 44% organic growth in equipment orders, UBS questions if the margin uptick can continue. The bank highlights that improved margins were driven mainly by better production absorption of fixed costs and a more favorable equipment-to-service sales mix, raising doubts about durability.

UBS spotlighted four key earnings risks: first, consensus profit margins for equipment and services look overly optimistic for 2026 and 2027 when compared to their more cautious estimates. Second, high expectations for Q2 equipment order growth have yet to be supported by large new contracts. Third, they reference that equipment book-to-bill ratios became positive only recently, implying modest revenue growth ahead. Lastly, UBS remains unconvinced that Epiroc will outpace peers like Sandvik on copper-driven growth given comparably easier benchmarks for Sandvik.

The broker made minor tweaks upwards on earnings for 2027 and 2028 but still forecasts EBIT results below consensus estimates for the three years between 2026 and 2028. Their upside target rests at SKr300, assuming strong 20% revenue growth and margin expansion, while the downside scenario could see the stock slide to SKr170 if growth stalls.

This puts the spotlight on whether recent gains are justified, or if the market is pricing in a best-case scenario that's a stretch. The mixed signals between solid order books and margin sustainability challenges add layers of complexity to Epiroc's outlook.

Given this, Epiroc's stock performance over the coming quarters will be particularly telling-will fundamentals catch up to the valuation, or will UBS's caution prove prescient?